Inflammation-based Indexes Upon Adjuvant Chemotherapy Initiation as a Predictor of Relapse After Curative Resection of Colorectal Cancer With an Oxaliplatin-based Regimen

Satake, Masaya; Yoshimatsu, Kazuhiko; Sagawa, Masano; Yokomizo, H; Shiozawa, Shunichi

doi:10.21873/cdp.10077

Cited by 3 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, this study developed a CRC prediction model and examined the connection between LAR and prognosis in CRC patients. The findings demonstrated that LAR is a significant showed that PLR measurement after adjuvant therapy could predict the recurrence of CRC after surgical treatment (31). The inconsistencies in the findings may be related to population characteristics.…”

Section: Discussionmentioning

confidence: 90%

The value of lactate dehydrogenase to albumin ratio and immune inflammation biomarkers in colorectal cancer

Ai²,

Wang³

et al. 2023

Front. Surg.

View full text Add to dashboard Cite

BackgroundColorectal cancer (CRC) is one of the most prevalent gastrointestinal cancers. Evidence for the importance of inflammation and immunology in the development and progression of CRC is growing steadily. The purpose of this study was to determine the clinical importance of Lactic Dehydrogenase (LDH) to Albumin (ALB) Ratio (LAR) and immune-inflammation biomarkers (IIBs) in patients with CRC.MethodsThis study enrolled 382 CRC patients. The LAR was determined as the serum LDH(U/l) to ALB(g/l) ratio. We compared the levels of LAR and IIBs in different TNM stages and tumor differentiation. The relationship between LAR and IIBs and overall survival (OS) of CRC was determined by Cox regression models. A prognostic nomogram was created using the results of the multivariate analysis and the effectiveness of the nomogram was assessed using the ROC, calibration, and decision curves. We evaluated the relationship between LAR and IIBs and clinical features of CRC.ResultsThe levels of LAR, SII, NLR and PLR in TNM IV stage group (LAR:5.92 (5.23–8.24); SII: 1040.02 (499.51–1683.54); NLR: 2.87 (2.07–5.3); PLR:187.08 (125.31–276.63)) were significantly higher than those in other groups. LAR and NLR showed no significant difference in different tumor differentiation groups, while SII and PLR in undifferentiated groups (SII:543.72 (372.63–1110.20); PLR: 147.06 (106.04–203.92)) were significantly higher than those in well and moderate groups (SII: 474.29 (323.75–716.01); PLR: 126.28 (104.31–167.88)). LAR (HR = 1.317, 95% CI = 1.019–1.454), TNM stage (HR = 2.895, 95% CI = 1.838–4.559), age (HR = 1.766, 95% CI = 1.069–2.922) and lymphocytes (HR = 0.663, 95% CI = 0.456–0.963) were predictors of OS. IIBs, including SII, NLR, and PLR are independent of OS. The LAR-based nomogram AUCs of 1-year, 3-year and 5-year survival probabilities in the training cohort were 0.86, 0.72, and 0.71, respectively, and the AUCs of the validation cohort were 0.85, 0.71, and 0.69 respectively. The LAR-based nomogram's ROC curves and calibration curves demonstrated higher OS discriminative performance. The decision curves demonstrated greater net benefit in the survival prediction.ConclusionPreoperative LAR is a potential prognostic marker in CRC patients, while SII, NLR, and PLR are independent of OS. LAR was associated with tumor stage in CRC patients, but not with tumor differentiation.

show abstract

Section: Discussionmentioning

confidence: 90%

The value of lactate dehydrogenase to albumin ratio and immune inflammation biomarkers in colorectal cancer

Ai²,

Wang³

et al. 2023

Front. Surg.

View full text Add to dashboard Cite

show abstract

“…Oxaliplatin, as one of the derivatives of cisplatin, additionally inhibits both DNA and protein synthesis and has relatively higher e cacy of killing cancer cells proliferation in chemotherapy [7,8]. Curative resection of CRC is often followed by adjuvant chemotherapy mainly based on oxaliplatin, for example, CAPOX (oxaliplatin and capecitabine) [9]. Immune checkpoint inhibitors, recommended as the pioneering treatment, have shown better therapeutic activity in microsatellite instability-high (MSI-H) or de cient mismatch repair (dMMR) CRC patients [10].…”

Section: Introductionmentioning

confidence: 99%

Gamma-Aminobutyric Acid Type A Receptor Subunit Pi is a potential chemoresistance regulator in colorectal cancer

Wang

Zhen

et al. 2023

Mol Biol Rep

View full text Add to dashboard Cite

Background: Colorectal cancer (CRC) is one of the cancers with high morbidity and mortality worldwide.Chemotherapy is commonly used for metastatic or more advanced CRC. The mechanism of CRC chemoresistance is still under active investigation. Therefore, we identify and validate differentially expressed genes (DEGs) between oxaliplatin/5-FU resistant and sensitive cells.Methods and Results: Three datasets of colorectal cancer patients (GSE28691, GSE81006, and GSE77932) from Gene Expression Omnibus (GEO) database were analyzed and volcano plots for DEGs were generated using GEO2R tool. The intersection of three GEO datasets showed that GABRP was signi cantly upregulated in chemo-resistant CRC cells or patients with an adjusted p-value less than 0.01.The STRING website analyzed the potential protein-protein interaction (PPI) network with GABRP. The PPI network predicted ANKRD66, CLINT1, HAP1, PLCL1, GABARPAP, GABARAPL1, NSF, GABARAPL2, TRAK2, and CLIC3 had a high likelihood to interact with GABRP. Especially, GABARAP, GABARAPL1, ANKRD66, CLINT1, and CLIC3 were enriched as the most possible associated protein with GABRP among the networks. GABRP was signi cantly highly expressed in both oxaliplatin/5-FU resistant CRC cells than in those counterparts sensitive CRC cells using quantitative PCR (qPCR) analysis. Consistently, TCGA and oncomine database con rmed that high expression of GABRP in various cancer patients including CRC patients tends to have relatively lower survival and disease-free survival rate.Conclusion: We identify GABRP as a promising drug target to mediate oxaliplatin or 5-FU resistance in CRC. It provided the theoretical basis and potential clinical value for CRC patients.

show abstract

GABRP is a potential chemoresistance regulator in colorectal cancer

Wang

Zhen

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Colorectal cancer (CRC) is one of the cancers with high morbidity and mortality worldwide. Chemotherapy is commonly used for metastatic or more advanced CRC. The mechanism of CRC chemoresistance is still under active investigation. Therefore, we identify and validate differentially expressed genes (DEGs) between oxaliplatin/5-FU resistant and sensitive cells.Methods and Results: Three datasets of colorectal cancer patients (GSE28691, GSE81006, and GSE77932) from Gene Expression Omnibus (GEO) database were analyzed and volcano plots for DEGs were generated using GEO2R tool. The intersection of three GEO datasets showed that GABRP was significantly upregulated in chemo-resistant CRC cells or patients with an adjusted p-value less than 0.01. The STRING website analyzed the potential protein-protein interaction (PPI) network with GABRP. The PPI network predicted ANKRD66, CLINT1, HAP1, PLCL1, GABARPAP, GABARAPL1, NSF, GABARAPL2, TRAK2, and CLIC3 had a high likelihood to interact with GABRP. Especially, GABARAP, GABARAPL1, ANKRD66, CLINT1, and CLIC3 were enriched as the most possible associated protein with GABRP among the networks. GABRP was significantly highly expressed in both oxaliplatin/5-FU resistant CRC cells than in those counterparts sensitive CRC cells using quantitative PCR (qPCR) analysis. Consistently, TCGA and oncomine database confirmed that high expression of GABRP in various cancer patients including CRC patients tends to have relatively lower survival and disease-free survival rate.Conclusion: We identify GABRP as a promising drug target to mediate oxaliplatin or 5-FU resistance in CRC. It provided the theoretical basis and potential clinical value for CRC patients.

show abstract

Inflammation-based Indexes Upon Adjuvant Chemotherapy Initiation as a Predictor of Relapse After Curative Resection of Colorectal Cancer With an Oxaliplatin-based Regimen

Cited by 3 publications

References 31 publications

The value of lactate dehydrogenase to albumin ratio and immune inflammation biomarkers in colorectal cancer

The value of lactate dehydrogenase to albumin ratio and immune inflammation biomarkers in colorectal cancer

Gamma-Aminobutyric Acid Type A Receptor Subunit Pi is a potential chemoresistance regulator in colorectal cancer

GABRP is a potential chemoresistance regulator in colorectal cancer

Contact Info

Product

Resources

About